"2024 was a pivotal year for Avadel, marked by consistent patient adoption of LUMRYZ and overwhelmingly positive feedback from both patients and providers about the transformative benefits of once ...

In a recent transaction reported to the Securities and Exchange Commission, Linda Palczuk, a director at Avadel ...

"Providing comprehensive support to patients and providers and continuously improving their experience with LUMRYZ is critical to Avadel’s success. Sev’s expertise in establishing and leading patient ...

Shares of Avadel Pharmaceuticals slumped after the company reported revenue targets for its narcolepsy treatment Lumryz that are below analyst estimates. The stock was down 25%, at $7.96 ...

The firm still believes that at current valuation, the stock is significantly cheap and can recover in the second half of 2025 as Lumryz growth starts to come back, but is now modeling peak Lumryz ...

Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21 ...

The revision follows Avadel's pre-announcement of flat fourth-quarter sales for its product Lumryz, which included an approximate $6 million inventory headwind. The company also issued sales ...

Legal actions against other defendants remain ongoing. Vandana Singh Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced that ...

Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 ...

Detailed price information for Avadel Pharmaceuticals Plc ADR (AVDL-Q) from The Globe and Mail including charting and trades.